Sunshine Lake Pharma Co (6887) investor relations material

Executive summary

• Revenue for the six months ended 30 June 2026 was RMB 1,075.31 million, down 44.5% year-over-year due to a sharp decline in sales of the core influenza drug Kewei following the easing of the epidemic.

• Gross profit fell 60.6% to RMB 578.17 million, and the period ended with a net loss attributable to equity shareholders of RMB 596.42 million, a significant increase from the prior year's loss.

• The company maintained a robust R&D pipeline, with notable progress in innovative drugs, AI-driven drug development, and international expansion, including FDA approval and US launch of Insulin Glargine.

• No interim dividend was declared for the period.

Financial highlights

• Revenue decreased 44.5% year-over-year to RMB 1,075.31 million.

• Gross profit dropped 60.6% to RMB 578.17 million.

• Loss before interest, tax, depreciation, and amortization was RMB 227.30 million, compared to a profit of RMB 430.05 million a year earlier.

• Net loss attributable to equity shareholders was RMB 596.42 million, up from a loss of RMB 54.27 million.

• Basic and diluted loss per share was RMB 1.09.

Outlook and guidance

• The company aims to strengthen its position as a vertically integrated pharmaceutical leader, focusing on innovation, internationalization, and AI-driven R&D.

• Plans include further investment in R&D, expanding global commercialization, and optimizing operational efficiency.